We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Germany has long been the only country in Europe that allows pharmaceutical producers to determine freely their prices for new, supposedly innovative products
